The Manila Times

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline D…

(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...
Taiwan News

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care First 45-subject data unblinding expected before June 30, 2026 ...

Acting CDC Director Jay Bhattacharya Called A Vaccine Study Design 'Crap.' What The Test-Negative Design Is And How We Know Whether Vaccines Measured With It Are Effective

Jay Bhattacharya dismissed the test-negative design as 'crap.' The biostatistics literature tells a different story.
MarketBeat on MSN

Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA ...
ahajournals.org

Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: The PRINCE Randomized Clinical Trial

Major noncardiac surgery is associated with high rates of postoperative myocardial injury and other complications. Remote ischemic preconditioning (RIPC) was reported to decrease these complication ...
Zacks Small Cap Research on MSN

CVKD: Designing phase 3 trial for CAD-1005 in HIT

By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Planning for Phase 3 Registration Trial ...